美国Eutropics   
开发了一种新的试验，以指导癌症治疗BH3分析生物标志物采用专有技术，以取代目前的治疗模式，提供更有针对性的治疗。

Eutropics Pharmaceuticals develops a novel test to guide cancer treatment by employing proprietary BH3-profiling biomarker technology to replace current treatment paradigms with more targeted therapy. The biomarker provides a unique understanding of cancer cells that will be important in the clinical stages of development and in guiding the use of marketed cancer drugs. The BH3 profiling assay also provides a biomarker that is important in the pre-clinical development of experimental drugs, including the company’s first in class anti-cancer therapeutic lead compound.

Cancer cells survive due to blocks that prevent apoptosis: the drugs Eutropics Pharmaceuticals is developing trigger cell death in cancer cells that otherwise elude control.

A unique and powerful assay guides clinicians in the use of the drugs. The assay establishes where apoptosis is blocked and what specific protein is the cause. This tells clinicians in advance which patients will respond to ours and current therapeutics.

Disease targets include blood cancers, small cell lung cancers and ovarian cancer.